Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
In the seven months since its founding the company has attracted $793m of financing. Now it must execute.
Almost $2bn was raised by drug developers in the third quarter, a period that witnessed two of the largest flotations of pre-revenue companies in recent years.
As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…
Private drug developers raised a record $8.5bn in the first half of 2018, amid a surge in mega rounds.